Botulinum toxin

Bibliographic InformationReason for rejecting study
Authors: Harper M;Popat RB;DasGupta R;Fowler CJ;Dasgupta P;. Title: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. Journal Name: BJU International. Year: 2003Purpose of study was to describe botulinum toxin administration under LA as an outpatient procedure in a series of 39 pts (26 F) with IDO or neurogenic DO. No clinical outcomes reported (all pts said to had 'marked improvement') - only numerical data for mean max cystometric capacity, but unclear at what time point.
Authors: Kessler TM;Danuser H;Schumacher M;Studer UE;Burkhard FC;. Title: Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity?. Journal Name: Neurourology and Urodynamics. Year: 2005Study compares outcomes of botulinum-A toxin in idiopathic vs neurogenic DO. 22 pts included (14 women); the proportion of women with idiopathic DO not stated & data not reported separately for this group of pts.
Authors: Kuo HC;. Title: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Journal Name: Urology. Year: 2004 MayOf 30 patients in the series, 18 were men & 12 overall had neurogenic bladder. Only limited results given for idiopathic DO subgroup, therefore study not considered further.
Authors: Smith CP;Nishiguchi J;O'Leary M;Yoshimura N;Chancellor MB;. Title: Single- institution experience in 110 patients with botulinum toxin a injection into bladder or urethra. Journal Name: Urology. Year: 2005Report includes 110 patients (75 women) treated with botulinum toxin; 74 patients had neurogenic bladder, 19 interstital cystitis or idiopathic retention/pelvic floor spasticity, leaving 17 with idiopathic OAB. Results not reported separately for OAB pts therefore study not helpful.
Authors: Schurch B, de Seze M, Denys P et al. Title: Botulimum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. Journal Name: J Urol. Year: 2005Only patients with neurogenic DO included in the study.

From: Excluded studies

Cover of Urinary Incontinence
Urinary Incontinence: The Management of Urinary Incontinence in Women.
NICE Clinical Guidelines, No. 40.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2006 Oct.
Copyright © 2006, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.